The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome.
Dell'Osso, Liliana, Bazzichi, Laura, Baroni, Stefano et al. · Clinical and experimental rheumatology · 2015
Quick Summary
This review examined whether ME/CFS, fibromyalgia, and mood disorders like depression might share similar root causes involving inflammation and immune system dysfunction. Researchers looked at scientific papers from 2000-2014 and found striking similarities in how these conditions affect the brain, nervous system, and immune system. The findings suggest these seemingly different conditions may be connected through common biological mechanisms rather than being completely separate diseases.
Why It Matters
This work validates patient experiences of overlapping symptoms across ME/CFS, fibromyalgia, and depression, and argues for integrated research and clinical approaches rather than siloed investigation. Recognition of shared inflammatory mechanisms could advance understanding of ME/CFS pathophysiology and inform more unified treatment strategies. For patients, this framework may reduce the fragmentation of care across different medical specialties.
Observed Findings
Literature identified overlapping features in neurotransmitter dysregulation (particularly serotonin and norepinephrine) across mood spectrum disorders, fibromyalgia, and ME/CFS.
Cytokine abnormalities and neuroinflammatory markers were documented in all three condition categories in published studies.
Shared involvement of central nervous system dysfunction alongside immune system activation was evident across conditions.
Clinical symptom overlap (fatigue, pain, cognitive dysfunction, mood disturbance) was notable across these diagnostic categories.
Inferred Conclusions
The borders between mood disorders, fibromyalgia, and ME/CFS should be reconsidered in light of shared pathophysiological mechanisms.
Both central nervous system and peripheral immune system dysfunction appear to be common features linking these conditions.
Integrated research approaches examining these conditions together may reveal disease mechanisms missed by conventional siloed investigation.
Common underlying inflammatory and neuroinflammatory processes may explain the high comorbidity rates observed clinically.
Remaining Questions
Which inflammatory markers or cytokine patterns are most specific or diagnostic for ME/CFS versus fibromyalgia versus mood disorders?
What This Study Does Not Prove
This review does not establish causation or prove that inflammation is the primary driver of ME/CFS, only that inflammation appears in the literature alongside these conditions. It does not provide new experimental data; it synthesizes existing published work, which may contain publication bias favoring positive findings. The review does not determine whether inflammatory markers are disease-causing, disease-modifying, or merely associated phenomena.
Do inflammatory mechanisms differ in their timing, intensity, or trajectory across these three conditions, and do these differences explain phenotypic variation?
What is the causal hierarchy—does inflammation cause these conditions, or do these conditions trigger inflammatory responses, or both?
Could targeting shared inflammatory pathways with specific anti-inflammatory therapies benefit ME/CFS patients, and what clinical trials are needed to test this?